These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16301869)

  • 1. Sporadic breast cancer among relatives of BRCA mutation carriers.
    Allweis TM; Sagi M; Peretz T
    Genet Med; 2005; 7(9):655-6. PubMed ID: 16301869
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.
    Neuhausen SL; Ozcelik H; Southey MC; John EM; Godwin AK; Chung W; Iriondo-Perez J; Miron A; Santella RM; Whittemore A; Andrulis IL; Buys SS; Daly MB; Hopper JL; Seminara D; Senie RT; Terry MB;
    Breast Cancer Res Treat; 2009 Jul; 116(2):379-86. PubMed ID: 18704680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.
    Rennert G; Dishon S; Rennert HS; Fares F
    Eur J Cancer Prev; 2005 Aug; 14(4):357-61. PubMed ID: 16030426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
    Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
    Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer risks for BRCA1/2 carriers.
    Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
    [No Abstract]   [Full Text] [Related]  

  • 10. One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers.
    Garber JE; Syngal S
    J Natl Cancer Inst; 2004 Jan; 96(1):2-3. PubMed ID: 14709725
    [No Abstract]   [Full Text] [Related]  

  • 11. Breast cancer risks for BRCA1/2 carriers.
    Easton DF; Hopper JL; Thomas DC; Antoniou A; Pharoah PD; Whittemore AS; Haile RW
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622557
    [No Abstract]   [Full Text] [Related]  

  • 12. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
    Smith M; Fawcett S; Sigalas E; Bell R; Devery S; Andrieska N; Winship I
    Fam Cancer; 2008; 7(2):119-24. PubMed ID: 17636421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer. A risky business--assessing breast cancer risk.
    Levy-Lahad E; Plon SE
    Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
    [No Abstract]   [Full Text] [Related]  

  • 14. BRCA1 and BRCA2: to test or not to test.
    Brandt RT; Lynch HT
    Breast Cancer Res Treat; 2001 May; 67(2):187-8. PubMed ID: 11519868
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
    Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
    Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
    Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast cancer in Jews.
    Rubinstein WS
    Fam Cancer; 2004; 3(3-4):249-57. PubMed ID: 15516849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.